By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Takeda Pharmaceutical Co. Ltd. 

1-1, Doshomachi 4-chome

Chuo-ku  Osaka  540-8645  Japan
Phone: 81-6-6204-2111 Fax: 81-6-6204-2880


Key Statistics

Email: n/a
Ownership: Public

Web Site: Takeda Pharmaceutical Co. Ltd.
Symbol: TKPYY


Company News
Takeda Pharmaceutical Co. Ltd. (TKPYY) Release: Additional Interim Data Supporting Long-Term Use Of Vedolizumab In Patients With Ulcerative Colitis And Crohn's Disease Published In Journal Of Crohn's And Colitis 9/29/2016 8:33:45 AM
Takeda Pharmaceutical Co. Ltd. (TKPYY) Release: Favorable Benefit: Risk Profile For Vedolizumab As Induction And Maintenance Therapy In TNF-Naïve Or TNF-Failure Patients With Moderately To Severely Active Ulcerative Colitis Published In Clinical Gastroenterology And Hepatology 9/16/2016 9:40:58 AM
Prosetta Biosciences And Takeda Pharmaceutical Co. Ltd. (TKPYY), Enter Into Agreement To Discover And Develop Novel Compounds For Neurodegenerative Diseases 5/2/2016 6:09:15 AM
Takeda Pharmaceutical Co. Ltd. (TKPYY) Celebrates Fifth Annual Takeda Cares Day By Expanding Nationwide And Raising More Than $250,000 For Chicagoland Nonprofits 10/2/2015 7:25:07 AM
Takeda Pharmaceutical Co. Ltd. (TKPYY): New Drug Application Approval In Japan For Copaxone Subcutaneous Injection 20 Mg Syringe, A Drug For The Treatment Of Multiple Sclerosis 9/28/2015 1:19:57 PM
Takeda Pharmaceutical Co. Ltd. (TKPYY) Release: FDA Accepts A Supplemental New Drug Application For Review of Brintellix (vortioxetine) Clinical Trial Data That Assessed Cognitive Function In Patients With Major Depressive Disorder 8/11/2015 6:47:14 AM
Takeda Pharmaceutical Co. Ltd. (TKPYY) Hosts Investor Briefing On Its Global Leadership In Gastroenterology 3/9/2015 11:26:53 AM
Prasco Laboratories And Takeda Pharmaceutical Co. Ltd. (TKPYY) Enter Into Agreement To Market Authorized Generic Of Colcrys® (Colchicine, USP) In The United States 1/12/2015 8:39:37 AM
Mersana Therapeutics, Inc., Takeda Pharmaceutical Co. Ltd. (TKPYY) Expand Antibody-Drug Pact By $300 Million 1/12/2015 6:17:41 AM
Seattle Genetics, Inc. (SGEN), Takeda Pharmaceutical Co. Ltd. (TKPYY) ADCETRIS Phase 3 Demonstrated Statistically Significant Improvement In Progression-Free Survival 12/9/2014 8:06:20 AM